Atomo Diagnostics offers a high-risk, high-asymmetry turnaround built on patented blood-based rapid testing, FebriDx-driven OEM scale-up, and major execution-dependent catalysts.
Overview
Atomo Diagnostics is an Australian point-of-care diagnostics company commercializing integrated rapid blood-testing platforms for self-test and OEM markets. Its Pascal cassette combines lancet, blood collection, buffer delivery, and lateral flow testing into one device, reducing user error versus traditional multi-component tests. Revenue comes from finished HIV tests, OEM cassette supply, and development fees across developed and Global Health markets. The company targets infectious disease, respiratory infection, and women’s health diagnostics, with usability, safety, and clinical reliability forming its core differentiation.